Fate Therapeutics Executive Compensation Details
Ticker: FATE · Form: DEF 14A · Filed: Apr 17, 2025 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | DEF 14A |
| Filed Date | Apr 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, def-14a, equity-awards
TL;DR
Fate Therapeutics DEF 14A out: Exec comp details for FY24, focus on equity awards.
AI Summary
Fate Therapeutics Inc. filed its DEF 14A on April 17, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted and outstanding, with a focus on fair value calculations as of various dates. Specific dollar amounts and dates related to these awards are presented within the compensation tables.
Why It Matters
This filing provides transparency into how Fate Therapeutics compensates its top executives, which can influence investor decisions and perceptions of the company's financial health and management strategy.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures about executive compensation and corporate governance, but can sometimes reveal information about potential financial pressures or strategic shifts that may impact stock price.
Key Numbers
- FY24 — Fiscal Year (Executive compensation details pertain to this period.)
- 2022-01-01 to 2022-12-31 — Reporting Period (Data presented for equity awards and their fair values.)
Key Players & Entities
- Fate Therapeutics Inc. (company) — Filer of the DEF 14A
- 0001193125-25-084310 (filing_id) — Accession Number for the filing
- 20250417 (date) — Filing Date
- 20250529 (date) — Reported Period End Date
- 1231 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing for Fate Therapeutics Inc.?
The primary purpose is to provide detailed information regarding the company's executive compensation, director compensation, and corporate governance practices for the fiscal year ending December 31, 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 17, 2025.
What is the fiscal year end for Fate Therapeutics Inc. as indicated in the filing?
The fiscal year end for Fate Therapeutics Inc. is December 31 (1231).
What type of compensation details are prominently featured in the filing?
The filing prominently features details on equity awards, including their fair value calculations, changes in fair value, and vesting conditions for the covered years.
What is the SIC code for Fate Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Fate Therapeutics Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 17, 2025 regarding FATE THERAPEUTICS INC (FATE).